Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5004650 | 0.98 | PTPN1 (0.42) | PTPN1HSD17B3MEN1KMT2AGRIN2B | |
| Bromide SCHEMBL3845607 | 0.98 | PTPN1 (0.42) | PTPN1HSD17B3MEN1KMT2AGRIN2B | |
| SCHEMBL6938200 | 0.87 | ALDH1A1 (0.49) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL1820216 | 0.86 | ALDH1A1 (0.46) | PTPN1MEN1KMT2AGRIN2BNPC1 | |
| Bromide SCHEMBL3851561 | 0.85 | MAPT (0.50) | MEN1KMT2ANPC1RAB9AKDM4E | |
| Bromide SCHEMBL3849504 | 0.85 | PTPN1 (0.44) | PTPN1MEN1KMT2ANPC1RAB9A | |
| Bromide SCHEMBL2954276 | 0.85 | ALDH1A1 (0.48) | PTPN1MEN1KMT2AGRIN2BNPC1 | |
| Hydrochloric Acid SCHEMBL33828 | 0.85 | RAB9A (0.46) | PTPN1MEN1KMT2AGRIN2BNPC1 | |
| Bromide SCHEMBL3849448 | 0.84 | CA12 (0.36) | MEN1KMT2AGRIN2BNPC1RAB9A | |
| Bromide SCHEMBL3845606 | 0.83 | ALDH1A1 (0.60) | MEN1KMT2AGRIN2BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-05-09 | — | — | US | claimed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6458819-B1 | INHIBITION OF FORMATION OF ADVANCED GLYCOSYLATION OF PROTEINS AND TO BREAKING THE CROSS-LINKS THAT FORM BETWEEN ADVANCED GLYCOSYLATION ENDPRODUCTS OR BETWEEN AGES AND OTHER PROTEINS. | ALTEON, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | TTR, RBP4, COL2A1 | PTPN1 2572/4885HSD17B3 4004/4885MEN1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.